References
- Barcza, L., Buvári-Barcza, A., & Gyarmathy, D. B. (1994). Hydroxy propyl β-cyclodextrins: Correlation between the stability of their inclusion complexes with phenolphthalein and the degree of substitution. Journal of Inclusion Phenomena and Molecular Recognition in Chemistry, 18(3), 301–306. doi:10.1007/BF00708736
- Duhovny, D., Nussinov, R., & Wolfson, H. J. (2002). In Gusfield (Ed). Proceedings of the 2'nd Workshop on Algorithms in Bioinformatics(WABI), Rome, Italy, Lecture Notes in Computer Science, 2452 (pp. 185–200). Berlin: Springer Verlag.
- El-Ezbawy, S. R., & Alshaikh, M. A. (1990). Synthesis and biological activity of some new 2-chlorophenothiazine derivatives. Journal of Chemical Technology & Biotechnology, 47(3), 209–218. doi:10.1002/jctb.280470303
- Figueiras, A. (2017). Methyl-β-cyclodextrin inclusion complex with β-caryophyllene: Preparation, characterization, and improvement of pharmacological activities. ACS Omega, 2, 9080–9094. doi:10.1021/acsomega.7b01438
- Hall, H., Hals, P., & Dahl, S. G. (1986). Phenothiazine drug metabolites: Dopamine d2 receptor, α1- and α2- adrenoceptor binding. European Journal of Pharmacology, 125, 373–381. doi:10.1016/0014-2999(86)90793-4
- Liu, L., & Zhu, S. (2006). Preparation and characterization of inclusion complexes of prazosin hydrochloride with β-cyclodextrin and hydroxypropyl-β-cyclodextrin. Journal of Pharmaceutical and Biomedical Analysis, 40(1), 122–127. doi:10.1016/j.jpba.2005.06.022
- Lok, A. S., & Ng, I. O. (1988). Prochlorperazine-induced chronic cholestasis. Journal of Hepatology, 6(3), 369–373. doi:10.1016/S0168-8278(88)80056-4
- Marwick K. F., Taylor, M., & Walker, S. W. (2012). Antipsychotics and abnormal liver function tests: Systematic review. Clinical Neuropharmacology, 35(5), 244–253. doi:10.1097/WNF.0b013e31826818b6
- Nagarsenker, M. S., Meshram, R. N., & Ramprakash, G. (2000). Solid dispersion of hydroxypropyl beta-cyclodextrin and ketorolac: Enhancement of in-vitro dissolution rates, improvement in anti-inflammatory activity and reduction in ulcerogenicity in rats. Journal of Pharmacy and Pharmacology, 52, 949–956. doi:10.1211/002235700177483
- Ranson, M., Locke, J. M., Stutchbury, T. K., Vine, K. L., Gamble, A. B., Clingan, P. R., & Bremner, J. B. (2009). Development and assessment of novel all-in-one parenteral formulations with integrated anticoagulant properties for the concomitant delivery of 5-fluorouracil and calcium folinate. Anti-Cancer Drugs, 20, 822–831. doi:10.1097/CAD.0b013e32832fd78e
- Szejtli, J., Gerlóczy, A., Sebestyén, G., & Fónagy, A. (1981). Influencing of resorption and side-effects of salicylic acid by complexing with beta-cyclodextrin. Die Pharmazie, 36(4), 283–286.
- Telles-Correia, D., Barbosa, A., Cortez-Pinto, H., Campos, C., Rocha, N. B. F., & Machado, S. (2017). Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity. World Journal of Gastrointestinal Pharmacology and Therapeutics, 81, 26–38. doi:10.4292/wjgpt.v8.i1.26
- Uekama, K., Nagase, Y., Arima, H., Wada, K., Sugawara, T., Satoh, H., & Hirayama, F. (2003). Inhibitory effect of sulfobutyl ether beta-cyclodextrin on DY-9760e-induced cellular damage: In vitro and in vivo studies. Journal of Pharmaceutical Sciences, 92, 2466–2474. doi:10.1002/jps.10517
- Wang, J., Xu, R., & Xu, A. (2017). Solubility determination and thermodynamic functions of 2-chlorophenothiazine in nine organic solvents from T = 283.15 K to T = 318.15 K and mixing properties of solutions. Journal of Chemical Thermodynamics, 106, 132–144. doi:10.1016/j.jct.2016.11.029
- Wu, Z., Tucker, I. G., Razzak, M., Yang, L., McSporran, K., & Medlicott, N. J. (2010). Absorption and tissue tolerance of ricobendazole in the presence of hydroxypropyl-β-cyclodextrin following subcutaneous injection in sheep. International Journal of Pharmaceutics, 397(1–2), 96–102. doi:10.1016/j.ijpharm.2010.07.002